REGENERON PHARMACEUTICALS, INC. Interest Expense Nonoperating
REGENERON PHARMACEUTICALS, INC. (REGN) reported Interest Expense Nonoperating of $11.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $11.00M, a 205.56% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $12.90M, a 48.28% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $12.20M, a 16.19% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $19.30M, a 39.86% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2025 was $43.80M, a 20.65% decline from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2024 was $55.20M, a 24.38% decline from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2023 was $73.00M, a 22.90% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2022 was $59.40M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.00M 10-Q · filed 2026-07-30 | $23.90M 10-Q · filed 2026-07-30 | $36.10M derived: sum of 3 quarters · filed 2026-07-30 | $55.40M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $12.90M 10-Q · filed 2026-04-29 | $25.10M derived: sum of 2 quarters · filed 2026-04-29 | $44.40M derived: sum of 3 quarters · filed 2026-04-29 | $48.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $12.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $31.50M derived: sum of 2 quarters · filed 2026-02-04 | $35.10M derived: sum of 3 quarters · filed 2026-07-30 | $43.80M 10-K · filed 2026-02-04 |
| 2025-09-30 | $19.30M 10-Q · filed 2025-10-28 | $22.90M derived: sum of 2 quarters · filed 2026-07-30 | $31.60M 10-Q · filed 2025-10-28 | $42.10M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $3.60M 10-Q · filed 2026-07-30 | $12.30M 10-Q · filed 2026-07-30 | $22.80M derived: sum of 3 quarters · filed 2026-07-30 | $36.60M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $8.70M 10-Q · filed 2026-04-29 | $19.20M derived: sum of 2 quarters · filed 2026-04-29 | $33.00M derived: sum of 3 quarters · filed 2026-04-29 | $47.80M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $10.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $24.30M derived: sum of 2 quarters · filed 2026-02-04 | $39.10M derived: sum of 3 quarters · filed 2026-02-04 | $55.20M 10-K · filed 2026-02-04 |
| 2024-09-30 | $13.80M 10-Q · filed 2025-10-28 | $28.60M derived: sum of 2 quarters · filed 2025-10-28 | $44.70M 10-Q · filed 2025-10-28 | $63.00M derived: sum of 4 quarters · filed 2026-02-04 |
| 2024-06-30 | $14.80M 10-Q · filed 2025-08-01 | $30.90M 10-Q · filed 2025-08-01 | $49.20M derived: sum of 3 quarters · filed 2026-02-04 | $67.00M derived: sum of 4 quarters · filed 2026-02-04 |
| 2024-03-31 | $16.10M 10-Q · filed 2025-04-29 | $34.40M derived: sum of 2 quarters · filed 2026-02-04 | $52.20M derived: sum of 3 quarters · filed 2026-02-04 | $71.10M derived: sum of 4 quarters · filed 2026-02-04 |
| 2023-12-31 | $18.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $36.10M derived: sum of 2 quarters · filed 2026-02-04 | $55.00M derived: sum of 3 quarters · filed 2026-02-04 | $73.00M 10-K · filed 2026-02-04 |
| 2023-09-30 | $17.80M 10-Q · filed 2024-10-31 | $36.70M derived: sum of 2 quarters · filed 2024-10-31 | $54.70M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $18.90M 10-Q · filed 2024-08-01 | $36.90M 10-Q · filed 2024-08-01 | ||
| 2022-12-31 | $59.40M 10-K · filed 2025-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |